List of Fibricor drug patents

Fibricor is owned by Athena.

Fibricor contains Fenofibric Acid.

Fibricor has a total of 4 drug patents out of which 0 drug patents have expired.

Fibricor was authorised for market use on 14 August, 2009.

Fibricor is available in tablet;oral dosage forms.

Fibricor can be used as adjunctive therapy to diet in patients with hyperlipidemias, adjunctive therapy to diet in patients with hyperlipidemias; adjunctive therapy to diet in patients with mixed dyslipidemia; adjunctive therapy to diet to patients with hypertriglyceridemia, adjunctive therapy to diet in patients with mixed dyslipidemia; adjunctive therapy to diet in patients with elevated cholesterol and/or lipid levels, adjunctive therapy to diet to patients with hypertriglyceridemia.

The generics of Fibricor are possible to be released after 20 August, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7569612 ATHENA Methods of use of fenofibric acid
Aug, 2027

(4 years from now)

US7741374 ATHENA Methods of use of fenofibric acid
Aug, 2027

(4 years from now)

US7741373 ATHENA Methods of use of fenofibric acid
Aug, 2027

(4 years from now)

US7915247 ATHENA Methods of use of fenofibric acid
Aug, 2027

(4 years from now)

Do you want to check out FIBRICOR patents from before 2022?

Drugs and Companies using FENOFIBRIC ACID ingredient

Market Authorisation Date: 14 August, 2009

Treatment: Adjunctive therapy to diet in patients with hyperlipidemias; Adjunctive therapy to diet in patients with mixed dyslipidemia; Adjunctive therapy to diet in patients with elevated cholesterol and/or lip...

Dosage: TABLET;ORAL

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in